Figure 1From: Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reportsLack of efficacy or adverse event discontinuation: placebo. Shown are the percentages of patients remaining in the studies conducted over 4 to 12 weeks with placebo after withdrawal because of lack of efficacy (LoE) or an adverse event (AE). CLBP, chronic low back pain; OA, osteoarthritis; RA, rheumatoid arthritis.Back to article page